| Literature DB >> 29118447 |
Marta Soszynska-Jozwiak1, Paula Michalak1, Walter N Moss2, Ryszard Kierzek1, Julita Kesy1, Elzbieta Kierzek3.
Abstract
Influenza A virus is a threat for humans due to seasonal epidemics and occasional pandemics. This virus can generate new strains that are dangerous through nucleotide/amino acid changes or through segmental recombination of the viral RNA genome. It is important to gain wider knowledge about influenza virus RNA to create new strategies for drugs that will inhibit its spread. Here, we present the experimentally determined secondary structure of the influenza segment 5 (+)RNA. Two RNAs were studied: the full-length segment 5 (+)RNA and a shorter construct containing only the coding region. Chemical mapping data combined with thermodynamic energy minimization were used in secondary structure prediction. Sequence/structure analysis showed that the determined secondary structure of segment 5 (+)RNA is mostly conserved between influenza virus type A strains. Microarray mapping and RNase H cleavage identified accessible sites for oligonucleotides in the revealed secondary structure of segment 5 (+)RNA. Antisense oligonucleotides were designed based on the secondary structure model and tested against influenza virus in cell culture. Inhibition of influenza virus proliferation was noticed, identifying good targets for antisense strategies. Effective target sites fall within two domains, which are conserved in sequence/structure indicating their importance to the virus.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29118447 PMCID: PMC5678188 DOI: 10.1038/s41598-017-15317-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Self-folding of (+)RNA5 predicted by RNAstructure 5.5 using experimental data obtained in 23 °C as constraints. Strong DMS, CMCT and kethoxal modifications, as well as SHAPE reactivities converted to pseudo-free energies were used. Additionally medium reactivity DMS, CMCT, kethoxal and results from RNase H cleavage in presence of DNA oligonucleotides (neither used in modeling) are also annotated. Red lines indicate regions of structure that differ at higher temperature (37 °C). The numbering of (+)RNA5 is from its 5′ end. The AUG start codon spans nucleotides 46–48.
Figure 2Chemical modifications data at 23 °C with NMIA for (+)RNA5 detected by reverse transcription with labeled primers followed by capillary electrophoresis. (A) Example of capillary electrophoresis raw data for nt 311–222 showing modified RNA (dark green line), unmodified control (light green line) and dideoxy ladders (C – red line and U – black line). (B) (+)RNA5 nt reactivities from SHAPE for the same region showed in panel A, in reverse order (222–311 nt) on the graph. (C) (+)RNA5 nt reactivities for SHAPE across the entire (+)RNA5. The nt region (222–311) showed on panel B is marked by line.
Figure 3Predicted probability of nt being paired or single stranded in (+)RNA5 using RNAstructure program. Probability lower than 50% is not colored. The partition function calculation incorporated restraints from strong reactivity of DMS, CMCT, kethoxal and SHAPE (converted to pseudo-energy).
Figure 4Conservation of (+)RNA5 secondary structure in type A of influenza viruses. Colors indicate percentage of canonical base pairing preserved across influenza A sequences for (+)RNA segment 5.
Deduced strong and medium binding sites in (+)RNA5 for microarray probes.
| Binding sitea,b | Confirmed binding sitesb,c | Strength of probe bindingd | Probe sequencee | Predicted ΔG°37 of probe/(+)RNA5 duplex (kcal/mol) for confirmed binding sitesf | RNase H cleavage sites |
|---|---|---|---|---|---|
| 154/1202 | 154 | M | CcCdA | −8.23 (154) | 157 |
| 155/791 | 155 | S | uCcCa | −8.86 (155) | 157 |
| 156/207/1430 | 156 | S | CUcCc | −9.16 (156) | 157 |
| 264 | 264 | M | UcUuUcA | −9.12 (264) | 262–264 |
| 13/601/930 | 601 | M | UdCcCg | −9.85 (601) | 604–605 |
| 365/501/753/778/1311 | 365 | M | GcUcUg | −10.26 (365) | 365 |
| 237/344/364/366/424/500/668/705/775/777/845/921/923 | 424/845/921/923 | S | CUcUcg | −9.08 (424/845/921/923) | 422/847/924–926 |
| 343/389/423/568/667/1515 | 423 | S | UcUcCg | −9.81 (423) | 422/847/924–926 |
| 386/425/669/846/1089/1110/1128/1243/1526 | 425 846 | M | CcUcUg | −10.09 (425, 846) | 422/847/924–926 |
| 341/387/398/426/, 566/847/1062/, 1111/1225/1367/1527 | 426 847 | M | uCcUcg | (−9.99) 426 (−9.99) 847 | 422/847/924–926 |
| 206/605/644/728/1091 | 644 | S | UcCcUg | −10.47 (644) | 642 |
| 645 | 645 | S | AuCcCg | −9.11 (645) | 642 |
| 880/1556 | 880 | S | DcDdGg | −7.73 (880) | 880 |
apossible complementary binding sites of probes, bsites are denoted by the middle nucleotide of the complementary RNA region (or two nucleotides for probes with an even number of nucleotides); cdeduced binding site for probe by comparison with DNA induced RNase H cleavage results; dbinding was considered strong (S), medium (M) and weak (W), when the integrated intensities were ≥1/3, ≥1/9 and ≥1/27 of the strongest intensity. Hybridization condition: buffer 300 mM KCl, 5 mM MgCl2, 50 mM HEPES, pH 7.0, 37 °C; enucleotides in capital letter (A, C, G, U, D) are 2′-O-methyl-RNA nucleotides, lower case letters (a, c, g, u, d) are LNA nucleotides, D and d are 2,6-diaminopurine (2′-O-methyl type or LNA, respectively); fΔG°37 calculated as modified probe/RNA duplex[35,36], in parenthesis, the site of binding for which calculation was done.
Figure 5(+)RNA5 accessibility to oligonucleotides. Results from microarray mapping and RNase H cleavage in presence of DNA oligonucleotides at 37 °C are annotated. Additionally, target regions for designed ASOs are showed in the context of (+)RNA5 structure. Binding sites of pentamer probes are denoted by the middle nucleotide of the five nucleotides complementary in the RNA. In case of hexamer probes, binding sites are denoted by the fourth complementary nt in the RNA. Site 264 binds a heptamer and the middle nt of the seven nt complementary in the RNA is marked. The red line indicates regions of structure difference upon higher temperature (37 °C).
ASOs targeting (+)RNA5.
| Name | Length (nt) | Sequence 5′ → 3′a | Complementary (+)RNA5 regionb | Conservation in target region nucleotide sequencec (%) |
|---|---|---|---|---|
| 1430A | 17 | CGaAGAcUCCcCGcCCC | 1427–1439 | 97.9 |
| 85A | 11 | CCaGUcUCcAU | 82–92 | 94.0 |
| 150A | 18 | CUcCCGAUUcCACcAAUC | 140–158 | 90.3 |
| 200A | 13 | CCaUCaUAAuCAC | 194–206 | 89.6 |
| 285A | 11 | UGcUCuUCuAG | 280–290 | 91.3 |
| 355A | 16 | UUcUCuCAUcCACuUU | 352–370 | 88.0 |
| 415A | 17 | UUcGCCaUUGuUUGCUU | 410–426 | 87.5 |
| 470A | 13 | CAuUCaGGUuGGA | 466–478 | 93.0 |
| 600A | 18 | GUuCCaACUcCUUuCACC | 591–608 | 87.6 |
| 615A | 13 | CUcCAuUGCuAUU | 609–621 | 88.6 |
| 640A | 17 | CCaCGUuUGAuCAUUCU | 628–644 | 86.7 |
| 760A | 19 | CCAuCAUuGCCcUCUgGGC | 745–763 | 93.1 |
| 840A | 12 | CCcCUcAGAaUG | 837–848 | 86.2 |
| 920A | 13 | CCuUCcCUUuCAA | 917–929 | 87.2 |
| 1320A | 21 | GCUGCCAuAACGGUUGCUCUU | 1308–1328 | 88.5 |
| 400A | 11 | CcAAAcUcUcC | 398–405 | 88.6 |
| 727A | 12 | AuUuUCcUuUGA | 722–732 | 91.6 |
| 950A | 14 | GAAuGGGuCUAuCC | 943–957 | 90.6 |
| 2A | 11 | CAuUCuCAuUU | 1146–1156 | 93.4 |
| 3A | 16 | CAuUCuCAuUUGAAGC | 1141–1156 | 95.2 |
| 2B | 11 | UCcAGgGUaUU | 1174–1184 | 88.2 |
| Neg5* | 11 | CUGaACGCuUA | 1262–1272 | 85.1 |
| N* | 17 | AGACCUCUAUAGCAGCU | — | — |
aNucleotides in capital letter (A, C, G, U, D) are 2′-O-methyl-RNA nucleotides, lower case letters (a, c, g, u, d) are LNA nucleotides, bnumbering according to (+)RNA5 *-control ASO, Neg5 is complementary to double stranded region, N is not effective oligonucleotide used as control in published paper[17]. cCalculated for type A influenza virus strains based on sequences database used in this study.
Figure 6Antiviral activity of 750 nM ASOs in MDCK cells for A/California/04/2009 after 24 h postinfection. Antiviral activity was analyzed by immunofocus assay. The mean was calculated from three independent experiments, each containing three technical repeats and the standard deviation is shown. C - MDCK cells infected by virus, L - MDCK cells treated with Lipofectamine 2000 and infected, Neg 5 – MDCK cells transfected with control ASO Neg 5 and infected, N - MDCK cells transfected with control ASO N and infected. The remaining labels indicate MDCK cells transfected with indicated influenza A targeting ASOs and infected. Statistics for comparison to sample L were calculated using a two-tailed T-test (p < 0.01).
Figure 7Antiviral activity of 750 nM ASOs in MDCK cells for A/California/04/2009 after 24 h postinfection. Antiviral activity was analyzed by qRT-PCR. The mean was calculated from three independent experiments each containing three technical repeats, each repeat was analyzed by three independent qRT-PCR reactions and the standard deviation is shown. C - MDCK cells infected by virus, L - MDCK cells treated with Lipofectamine 2000 and infected, Neg 5 – MDCK cells transfected with control ASO Neg 5 and infected, N - MDCK cells transfected with control ASO N and infected. The remaining labels indicate MDCK cells transfected with indicated influenza A targeting ASOs and infected. *Statistics for comparison to sample L were calculated using a two-tailed T-test (p < 0.01).